echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > "Pharmaceutical Speed ​​Reading Club" Rongchang and Zejing Biology are made in China

    "Pharmaceutical Speed ​​Reading Club" Rongchang and Zejing Biology are made in China

    • Last Update: 2021-06-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    [June 9, 2021/Medical Information List] Pfizer's 20-valent pneumococcal conjugate vaccine passed the US FDA approval; Incyte's Jakafi review application was postponed by the FDA for 3 months; 3D electronic abdominal endoscopy was approved for marketing; Blue Sail Medical Deputy President Yang Fan resigns.


    [June 9, 2021/Medical Information List] Daily news about fresh medicines and medical news, speed reading and follow you together!

    Part1 Policy Brief

    Part1 policy briefing Part1 policy briefing

    The three departments jointly issued a document to continue to improve the funding standards for residents' medical insurance in 2021

    The three departments jointly issued a document to continue to improve the funding standards for residents' medical insurance in 2021

    On the 8th, the National Medical Insurance Bureau and the Ministry of Finance jointly issued notices on improving the unified basic medical insurance system and critical illness insurance system for urban and rural residents, and earnestly doing a good job in medical security for urban and rural residents


    National Health Commission: Establish an expert group to promote the construction of a hierarchical diagnosis and treatment and medical consortium

    National Health Commission: Establish an expert group to promote the construction of a hierarchical diagnosis and treatment and medical consortium

    On June 7, the National Health Commission issued a notice on the establishment of an expert group to promote the construction of hierarchical diagnosis and treatment and medical consortia, which will evaluate and supervise the implementation of the national hierarchical diagnosis and treatment and medical consortium construction


    The State Food and Drug Administration issued an announcement on the cancellation of a medical device registration certificate

    The State Food and Drug Administration issued an announcement on the cancellation of a medical device registration certificate

    On June 9, the State Food and Drug Administration issued an announcement that, in accordance with the provisions of the "Medical Device Registration Management Measures," the registration number of Nikon Corporation is now cancelled according to the application of the enterprise: National Machinery Injection 20172226595, product name: Biomicroscope Medical Device registration certificate


    The genetic sequencing similarity of all positive cases in Guangzhou exceeds 98%

    The genetic sequencing similarity of all positive cases in Guangzhou exceeds 98%

    On June 9, Li Tiegang, deputy director of the Disease Control and Prevention Department of the Guangzhou Municipal Health Commission, said that at present, the genetic sequencing similarity of all positive cases in Guangzhou has reached more than 98%, that is to say, all positive cases have a chain of transmission


    Part2 Observation

    Part2 Sankei Observation Part2 Sankei Observation

    Yang Fan, Vice President of Blue Sail Medical, resigns

    Yang Fan, Vice President of Blue Sail Medical, resigns

    On June 8, Blue Sail Medical issued an announcement on the Shenzhen Stock Exchange stating that the company's vice president, Mr.


    Baiyang Pharmaceutical IPO plans to publicly issue 52.


    Baiyang Pharmaceutical IPO plans to publicly issue 52.


    Watson Pharmaceuticals: Signed the "Innovative Drug Development Strategic Cooperation Framework Agreement" with Zheyuan Technology and other parties

    Watson Pharmaceuticals: Signed the "Innovative Drug Development Strategic Cooperation Framework Agreement" with Zheyuan Technology and other parties

    On June 9, Watson Pharmaceuticals announced that the company, Beijing Zheyuan Technology Co.


    Haoyuan Pharmaceutical is listed on the Science and Technology Innovation Board

    Haoyuan Pharmaceutical is listed on the Science and Technology Innovation Board

    On June 8, Haoyuan Pharmaceutical was listed on the Science and Technology Innovation Board with the stock code 688131


    VVS Medical completed nearly 100 million yuan in A+ round of financing

    VVS Medical completed nearly 100 million yuan in A+ round of financing

    On June 9, Suzhou VVS Medical Technology Co.


    Part3 Medicine News

    Part3 Medicine News Part3 Medicine News

    A new generation of ADC in the treatment of HER2-positive breast cancer patients reaches phase 3 clinical endpoint

    A new generation of ADC in the treatment of HER2-positive breast cancer patients reaches phase 3 clinical endpoint

    On June 8, Byondis announced that its new generation of antibody conjugate drug trastuzumab duocarmazine had reached the primary endpoint of progression-free survival in the Phase 3 clinical study TULIP


    UK NICE approves Roche Tecentriq as first-line treatment for PD-L1-positive lung cancer

    UK NICE approves Roche Tecentriq as first-line treatment for PD-L1-positive lung cancer

    The National Institute of Health and Clinical Excellence recently issued guidelines recommending Roche’s anti-PD-L1 therapy Tecentriq as a monotherapy for the first-line treatment of metastatic non-small cell lung cancer


    Pfizer pneumococcal 20-valent conjugate vaccine approved by the U.


    Pfizer pneumococcal 20-valent conjugate vaccine approved by the U.


    Xinrui α-Radiation Cancer Therapy Receives FDA Breakthrough Medical Device Certification

    Xinrui α-Radiation Cancer Therapy Receives FDA Breakthrough Medical Device Certification

    Recently, Alpha Tau Medical announced that its alpha-radiation cancer therapy Alpha DaRT has received a breakthrough medical device designation granted by the US FDA, which is suitable for the treatment of skin and oral squamous cell carcinomas with no curative standard therapies


    Incyte's Jakafi review application was postponed by the FDA for 3 months

    Incyte's Jakafi review application was postponed by the FDA for 3 months

    Affected by the chain reaction of Pfizer’s Xeljanz negative safety signal, Incyte said on Tuesday that the FDA has also delayed the approval of Jakafi for the treatment of steroid-refractory chronic graft-versus-host disease by 3 months.
    Jakafi The new target decision date for this indication is September 22
    .
    (Sina Pharmaceutical News)

    first! Rongchang Bio-Injection Vidicuzumab is conditionally approved for marketing

    first! Rongchang Bio-Injection Vidicuzumab is conditionally approved for marketing

    On June 9th, the State Food and Drug Administration issued an announcement, conditionally approving the listing of vedicitumumab for injection declared by Rongchang Biologics
    .
    The drug is an innovative antibody conjugate drug independently developed by China, which is suitable for the treatment of locally advanced or metastatic gastric cancer patients with HER2 overexpression who have received at least 2 types of systemic chemotherapy
    .
    (National Food and Drug Administration)

    The State Food and Drug Administration approves the marketing of Donafinil tosylate tablets

    The State Food and Drug Administration approves the marketing of Donafinil tosylate tablets

    June 9, the State Food and Drug Administration official website announced recently by the State Food and Drug Administration priority review approval procedures Suzhou Ze Jing Biological Pharmaceutical Co.
    , Ltd.
    declared a Class 1 drug innovation toluene sulfonic acid Dona sorafenib tablets on the market
    .
    The drug is an innovative drug independently researched and developed by China with independent intellectual property rights.
    It is used for patients with unresectable hepatocellular carcinoma who have not received systemic treatment in the past
    .
    (National Food and Drug Administration)

    Another inactivated new crown vaccine in my country is on the market and uses 2 doses throughout the course of vaccination

    Another inactivated new crown vaccine in my country is on the market and uses 2 doses throughout the course of vaccination

    On June 9th, the first batch of Covifo's new coronavirus inactivated vaccine independently developed by the Institute of Biology of the Medical Academy was put on the market for emergency domestic use
    .
    The immunization procedure of the new crown inactivated vaccine developed by the Institute of Biology of the Academy of Medical Sciences is the same as that of similar vaccines.
    The whole course of inoculation is 2 doses, each dose is 2-4 weeks apart
    .
    The current vaccination age is 18 years old and above
    .
    (Sina Pharmaceutical News)

    Three-dimensional electronic laparoscopic endoscopy was approved for marketing

    Three-dimensional electronic laparoscopic endoscopy was approved for marketing

    June 8, the State Food and Drug Administration issued a public notice, after review, approve an application for registration of minimally invasive (Shanghai) Co.
    , Ltd.
    Medical robot innovative products, "three-dimensional electronic endoscope abdominal cavity," the
    .
    It is reported that the product provides images through a video monitor for observation, diagnosis, photography or treatment of the thoracic cavity and abdominal cavity
    .
    (National Food and Drug Administration)

    Tetrabenazine tablets are about to be approved for the treatment of Huntington's disease

    Tetrabenazine tablets are about to be approved for the treatment of Huntington's disease

    Recently, Shandong Bausch & Lomb Freda Pharmaceuticals has entered the administrative stage for the import application of the 5.
    1 new drug tetrabenazine tablets.
    It is expected that it will be formally approved in the near future, becoming the second domestic approved drug for the treatment of Huntington's disease
    .
    (CPhl Pharmaceutical Online)

    Winbond Health Methylprednisolone Sodium Succinate for Injection passed the consistency evaluation of generic drugs

    Winbond Health Methylprednisolone Sodium Succinate for Injection passed the consistency evaluation of generic drugs

    On June 9th, Winbond Health announced that Winbond Pharmaceuticals, a wholly-owned subsidiary, has recently received the "Drug Supplementary Application Approval Notice" approved and issued by the State Food and Drug Administration for injection of methylprednisolone sodium succinate.
    Pass the consistency evaluation of generic drugs
    .
    The drug is generally used clinically in the acute and critical phases of critically ill patients, as well as maintenance treatment after first aid
    .
    (Winbond Health Announcement)

    Bayer's innovative cell therapy and gene therapy enter clinical trials

    Bayer's innovative cell therapy and gene therapy enter clinical trials

    On June 8, Bayer announced that its BlueRock Therapeutics company had successfully transplanted DA01, a dopaminergic neuron therapy produced by pluripotent stem cells, to a Parkinson's disease patient for the first time in a phase 1 clinical trial
    .
    At the same time, its subsidiary Asklepios Biopharmaceuticals is also advancing gene therapy for the treatment of Parkinson's disease
    .
    (WuXi AppTec)

    Janssen BCMA/CD3 double antibody was approved for clinical use in China

    Janssen BCMA/CD3 double antibody was approved for clinical use in China

    CDE's official website announced that Johnson & Johnson's new class 1 biological drug teclistamab injection has been approved for clinical use, targeting multiple myeloma
    .
    It is reported that this is a bispecific antibody that targets the mature antigen of B cells and the CD3 receptor on the surface of T lymphocytes
    .
    (CDE official website)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.